MedTrace Logo

A Study in Participants With Rheumatoid Arthritis on Background Methotrexate Therapy

NCT01185353 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 301

Last updated 2017-06-16

Study results available
· View outcomes & findings →

Summary

The purpose of this trial is to evaluate the safety and efficacy of LY3009104 in participants with Rheumatoid Arthritis (RA).

Conditions

  • Arthritis, Rheumatoid

Interventions

DRUG

LY3009104

Administered orally

DRUG

Placebo

Administered orally

DRUG

Methotrexate

Administered orally as background therapy

Sponsors & Collaborators

Principal Investigators

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) · Eli Lilly and Company

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-10-31
Primary Completion
2011-12-31
Completion
2014-03-31

Countries

  • United States
  • Croatia
  • Czechia
  • Hungary
  • India
  • Mexico
  • Poland
  • Romania
  • Ukraine

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01185353 on ClinicalTrials.gov